Although the mechanism of benefi t is unclear, data support colchicine use in the management of recurrent pericarditis. Imazio et al. undertook a double blind trial of adults with acute pericarditis who were randomised to receive colchicine 0.5 mg twice daily (patient weight > 70 kg) or 0.5 mg daily (patient weight " 70 kg) for 3 months or placebo.
|Number of pages||1|
|Journal||Journal of Pharmacy Practice and Research|
|Publication status||Published - 2013|